Lemaitre Vascular (LMAT) Total Non-Current Liabilities (2010 - 2026)
Lemaitre Vascular's (LMAT) quarterly Total Non-Current Liabilities came in at $221.6 million in Q1 2026, up 6.76% year-on-year from $207.6 million in Q1 2025, and little changed on a QoQ basis from $220.7 million in Q4 2025.
Lemaitre Vascular (LMAT) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Lemaitre Vascular (LMAT) has 17 years of Total Non-Current Liabilities data on file, last reported at $221.6 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 6.76% year-over-year to $221.6 million in Q1 2026; TTM through Mar 2026 was $221.6 million, a 6.76% increase from a year earlier, with the FY2025 full-year figure at $220.7 million, up 3.28% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $221.6 million, roughly flat from $220.7 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for LMAT reached as high as $221.6 million in Q1 2026 and fell as low as $33.9 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $103.1 million across 5 years, with a median of $44.9 million in 2024.
- Across the five-year window, Total Non-Current Liabilities sank 51.37% in 2022 and soared 417.24% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $40.1 million in 2022, then climbed by 16.21% to $46.6 million in 2023, then jumped by 358.48% to $213.7 million in 2024, then increased by 3.28% to $220.7 million in 2025, then grew by 0.4% to $221.6 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $221.6 million in Q1 2026, $220.7 million in Q4 2025, and $218.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 6.48 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 1.92 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 48.37 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 17.13 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 941.16 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 4.24 Bn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 8.65 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 2.06 Bn |
| 10 | Lemaitre Vascular | 2.22 Bn | 1.86 Bn | 48.40 Mn | 221.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 221.59 Mn |
| Dec 31, 2025 | 220.71 Mn |
| Sep 30, 2025 | 218.21 Mn |
| Jun 30, 2025 | 213.97 Mn |
| Mar 31, 2025 | 207.56 Mn |
| Dec 31, 2024 | 213.70 Mn |
| Sep 30, 2024 | 45.69 Mn |
| Jun 30, 2024 | 41.37 Mn |
| Mar 31, 2024 | 44.86 Mn |
| Dec 31, 2023 | 46.61 Mn |
| Sep 30, 2023 | 43.23 Mn |
| Jun 30, 2023 | 42.06 Mn |
| Mar 31, 2023 | 40.51 Mn |
| Dec 31, 2022 | 40.11 Mn |
| Sep 30, 2022 | 38.40 Mn |
| Jun 30, 2022 | 40.70 Mn |
| Mar 31, 2022 | 33.90 Mn |
| Dec 31, 2021 | 38.51 Mn |
| Sep 30, 2021 | 40.29 Mn |
| Jun 30, 2021 | 60.54 Mn |